

**2007** ANNUAL  
CIRM  
SCHOLARS  
MEETING

CALIFORNIA INSTITUTE FOR



**CIRM**

REGENERATIVE MEDICINE

# Meetings

- Northern California Training Programs
  - Tuesday, September 11, 2007
  - UC San Francisco Mission Bay Campus
- Southern California Training Programs
  - Friday, September 28, 2007
  - UC Irvine Campus

# miR-1 Promotes and miR-133 Blocks Cardiac Differentiation in Embryoid Bodies







**Stem Cell in Acute Promyelocytic Leukemia is Mature Cell**  
 Galit Rosen MD, Scott Kogan, MD University of California, San Francisco



acute myeloid leukemia with a prognosis of 1-2 years. It is not clear if follows the same path as HSC, or that it originates from a cell of origin (leukemia) that is directed towards HSC. However, in acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia, the leukemia cells are myeloid precursors, not HSC. A widely used model (PR) of acute promyelocytic leukemia is the PM<sub>1</sub>/RARA model. We have shown that the LSC in this model (PR) of acute promyelocytic leukemia are myeloid precursors, not HSC.

**Progenitors are infrequent in acute promyelocytic leukemia**

**A**  **B** 



Progenitor FACS analysis of normal vs. leukemia cells. (A) F4/80 control bone marrow showing presence of HSC and myeloid progenitors (MP). (B) Leukemic spleen sample showing paucity of all hematopoietic progenitors.

**Progenitors also have expanded promyelocytes, but normal number of progenitors**

**A**  **B** 

(A) Progenitors in PM<sub>1</sub>/RARA mice have increased CD34<sup>+</sup>CD33<sup>+</sup> cells in the F4/80<sup>+</sup> progenitor. Right axis shows CD34<sup>+</sup>CD33<sup>+</sup> cells in the MP. (B) CD34<sup>+</sup>CD33<sup>+</sup> myeloid progenitors (MP) phenotype resembling progenitors. MP<sup>+</sup> megakaryocyte-erythroid progenitor. Area 100% expected population of PM<sub>1</sub>/RARA mice. (C) Control CD34<sup>+</sup>CD33<sup>+</sup> have morphology consistent with promyelocytes.

**LSC are lymphoerythroid ckit<sup>+</sup>Gr1<sup>+</sup>**

Survival curve of mice transplanted with fractionated cells from leukemic spleens. The ckit<sup>+</sup>Gr1<sup>+</sup> myeloblast population (blasts) is enriched for LSC. These mice have decreased survival compared to mice injected with whole unfractionated leukemia. Fractionated cells that have variable expression of ckit but lack Gr1 (MP are within this gate) are not enriched for LSC. Mice injected with these cells have similar survival to negative control injected with lymphocytes.

**Conclusion**

The leukemia stem cell in this mouse model of acute promyelocytic leukemia is a myeloid cell rather than a progenitor cell. There is expansion of progenitors in the leukemia cells, but this is a result of the action of promyelocytes. These cells are promyelocytes, not HSC. Further studies in order to determine whether a stem cell model is further supported in order to determine whether the effect of promyelocytes on the LSC. Subsequent work will study the effect of promyelocytes on the leukemia stem cell in comparison to leukemia stem cells and normal progenitors.

**Acknowledgments**

This work was supported by funding from the San Francisco Medical Research Inc., Zuyin, New York, and the California Institute of Regenerative Medicine.





034

### Intrapulmonary Treatment with Mesenchymal Stem Cells Reduces Endotoxin Induced Acute Lung Injury and Mortality in Mice

Michael A. Matthay<sup>1</sup>, Vladimir Serikov<sup>2</sup>, Michael A. Matthay<sup>1</sup>  
<sup>1</sup>Children's Hospital of Oakland Research Institute

**UCSF**

**RESULTS**

**Figure 1.** MSCs suppress airway hyper-responsiveness (AHR) in mice. ...

**Figure 2.** MSCs decrease the severity of endotoxin-induced acute lung injury. ...

**Figure 3.** MSCs decrease the severity of endotoxin-induced acute lung injury. ...

**Figure 4.** MSCs decrease the severity of endotoxin-induced acute lung injury. ...

**Figure 5.** MSCs decrease the severity of endotoxin-induced acute lung injury. ...

**Figure 6.** MSCs decrease the severity of endotoxin-induced acute lung injury. ...

**Figure 7.** MSCs decrease the severity of endotoxin-induced acute lung injury. ...

**CONCLUSIONS**

- MSCs suppress airway hyper-responsiveness (AHR) in mice.
- MSCs decrease the severity of endotoxin-induced acute lung injury.
- MSCs decrease the severity of endotoxin-induced acute lung injury.
- MSCs decrease the severity of endotoxin-induced acute lung injury.

## Regulating Stem Cell Differentiation through Expressing Engineered G<sub>s</sub>-coupled Receptor

Edward Hsiao, M.D., Ph.D.<sup>1,2</sup>, Benjamin M. Boudignon, Ph.D.<sup>4</sup>, Wei C. Chang, B.A.<sup>1,2</sup>, Yuko Yoshitoku<sup>1</sup>, Pieter DeJong, Ph.D.<sup>3</sup>, Bernard P. Halloran, Ph.D.<sup>4</sup>, Robert Nissenson, Ph.D.<sup>4</sup>, and Bruce M. Spiegel, M.D., Ph.D.<sup>1,2</sup>

<sup>1</sup>Gladstone Institute of Cardiovascular Disease, San Francisco, CA, <sup>2</sup>University of California, San Francisco, CA, <sup>3</sup>Children's Hospital of Oakland Research Institute, Oakland, CA, <sup>4</sup>Scripps Institution of Oceanography, San Diego, CA

**Introduction**

Understanding the regulation of tissue differentiation is a key goal in regenerative medicine. Signaling pathways such as G-protein-coupled receptors (GPCRs) are strongly implicated in development and disease. However, the mechanisms by which GPCRs regulate stem cell differentiation have not been well defined. Several G-protein-coupled receptors (GPCRs) are expressed in stem cells and muscle. We are developing mouse models to study the effects of signaling pathways on stem cell differentiation.

**Figure 2**

Engineered RASSL has G<sub>s</sub>-coupled basal signaling activity

**B**

**C**

**Figure 3**

Tetracycline-regulated stem cell differentiation

**Summary**

The G-protein G<sub>s</sub> signaling pathway is well established in multiple endocrine signaling within osteoblasts and is essential for bone formation. We are using a G<sub>s</sub> signaling pathway to regulate stem cell differentiation in osteoblasts.

**Background**

Abnormal G-protein signaling plays a central role in many developmental processes, including abnormal bone and cartilage formation (Weinstein, 2001; Rangel, 1996), and cartilage development (Saffin, 2002; Meador, 2005). However, the mechanisms by which G-protein signaling regulates stem cell differentiation have not been well defined.

**References and Acknowledgements**











protocols.

## Future CIRM Scholar



**2007** ANNUAL  
CIRM  
SCHOLARS  
MEETING

CALIFORNIA INSTITUTE FOR

**CIRM**

REGENERATIVE MEDICINE